Occurrence of Myocarditis after the Vaccine for COVID-19
Rapid Review of Incidence, Associated Risk Factors, and Clinical Course of Myocarditis and Pericarditis following COVID-19 vaccination
Project Status:Complete
Knowledge User(s)
Public Health Agency of Canada, National Advisory Committee on Immunization
Patient/Public Partner(s)
Linda Wilhelm, Natasha Trehan
Funding Source(s)
- Canadian Institutes of Health Research (CIHR) through COVID-END
- Canadian Institutes of Health Research (CIHR) through the Strategy for Patient-Oriented Research (SPOR) Evidence Alliance
Project Objectives
To determine what the incidence of myocarditis and pericarditis is after COVID-19 vaccination; whether the incidence varies by patient characteristics (e.g., age, sex) or vaccine factors (e.g., type of vaccine, dose); and the characteristics and short-term clinical course in patients with myocarditis and pericarditis after COVID-19 vaccination.
Research Approach
Rapid Review
Project Lead(s)
